NATIONAL CANCER POLICY FORUM¹

• MICHAEL CALIGIURI (Chair), Chief Executive Officer, James Cancer Hospital and Solove Research Institute; Director, The Ohio State University Comprehensive Cancer Center
• PATRICIA A. GANZ (Vice Chair), Distinguished Professor, University of California, Los Angeles, Fielding School of Public Health; Director, Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center
• AMY P. ABERNETHY, Chief Medical Officer and Senior Vice President for Oncology, Flatiron Health
• LUCILE ADAMS-CAMPBELL, Professor of Oncology, Associate Director for Minority Health and Health Disparities Research, Georgetown University Lombardi Cancer Center
• KENNETH ANDERSON, Kraft Family Professor of Medicine, American Cancer Society Clinical Research Director, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute
• MONICA M. BERTAGNOLLI, Richard E. Wilson Professor of Surgery, Harvard Medical School; Chief, Division of Surgical Oncology, Dana-Farber/Brigham and Women's Cancer Center; Group Chair, Alliance for Clinical Trials in Oncology
• OTIS W. BRAWLEY, Chief Medical Officer, American Cancer Society
• ROBERT W. CARLSON, Chief Executive Officer, National Comprehensive Cancer Network
• GREGORY CURT, Executive Director, External Scientific and Clinical Relations, U.S. Medical Affairs, AstraZeneca
• WENDY DEMARK-WAHNEFRIED, Professor and Webb Endowed Chair of Nutrition Sciences, Associate Director for Cancer Prevention and Control, University of Alabama at Birmingham Comprehensive Cancer Center
• GEORGE D. DEMETRI, Professor of Medicine, Harvard Medical School; Director, Ludwig Center; Senior Vice President for Experimental Therapeutics, Dana-Farber Cancer Institute; Associate Director for Clinical Sciences, Dana-Farber/Harvard Cancer Center
• JAMES H. DOROSHOW, Deputy Director for Clinical and Translational Research, National Cancer Institute
• JOHN FRIEND II, Senior Vice President, Helsinn Therapeutics
• LORI HOFFMAN HŌGG, Veterans Health Administration National Oncology Clinical Advisor and Program Manager, Prevention Policy, Department of Veterans Affairs
• LINDA HOUSE, President, Cancer Support Community
• HEDVIG HRICAK, Chair, Department of Radiology, Memorial Sloan Kettering Cancer Center
• LISA KENNEDY SHELDON, Chief Clinical Officer, Oncology Nursing Society; Editor, Clinical Journal of Oncology Nursing
• SAMIR N. KHLEIF, Professor of Medicine, Biochemistry, Molecular Biology, and Graduate Studies, Augusta University
• RONALD M. KLINE, Medical Officer, Patient Care Models Group, Center for Medicare & Medicaid Innovation, Centers for Medicare & Medicaid Services
• LEE M. KRUG, Disease Area Head, Lung and Head & Neck Cancer, Immuno-Oncology, Bristol-Myers Squibb
• RICHARD A. LARSON, Professor of Medicine and Director, Hematologic Malignancies Clinical Research Program, The University of Chicago Comprehensive Cancer Center
• MICHELLE M. LE BEAU, Arthur and Marian Edelstein Professor of Medicine and Director, The University of Chicago Comprehensive Cancer Center
• GRETA MASSETTI, Associate Director for Science, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention
• DANIEL R. MASYS, Affiliate Professor, Biomedical and Health Informatics, University of Washington School of Medicine
• MARTIN J. MURPHY, Chief Executive Officer, CEO Roundtable on Cancer
• LOYCE PACE, Executive Director, Global Health Council (LIVESTRONG Representative)
• RICHARD PAZDUR, Director, Oncology Center of Excellence; Acting Director, Office of Hematology and Oncology Products, Food and Drug Administration
• STEVEN PIANTADOSI, Phase One Foundation Endowed Chair and Director, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
• JENNIFER A. PIETENPOL, Director, Vanderbilt-Ingraham Cancer Center; Executive Vice President for Research, Vanderbilt University Medical Center; and Benjamin F. Byrd, Jr. Professor of Oncology, Vanderbilt University
• MACE L. ROTHENBERG, Chief Development Officer, Oncology, Pfizer Global Product Development, Pfizer Inc.
• RICHARD L. SCHILSKY, Senior Vice President and Chief Medical Officer, American Society of Clinical Oncology
• DEBORAH SCHRAG, Chief, Division of Population Sciences, Professor of Medicine, Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute
• YA-CHEN TINA SHIH, Professor of Health Economics, Chief, Section of Cancer Economics and Policy, Department of Health Services Research, University of Texas MD Anderson Cancer Center
• ELLEN V. SIGAL, Chair and Founder, Friends of Cancer Research
• RALPH WEICHSELBAUM, Daniel K. Ludwig Professor and Chair, Department of Radiation; Oncology and Cellular Director, Ludwig Center for Metastasis Research, The University of Chicago Medical Center
• GEORGE J. WEINER, President, Association of American Cancer Institutes; C.E. Block Chair of Cancer Research, Professor of Internal Medicine, and Director, Holden Comprehensive Cancer Center, University of Iowa
• RICHARD WOODMAN, Senior Vice President and Head, North America Oncology Clinical Development & Medical Affairs, Novartis Pharmaceuticals Corporation
• WENDY WOODWARD, Associate Professor and Section Chief of Clinical Breast Radiation, Department of Radiation Oncology, University of Texas MD Anderson Cancer Center

Footnotes

1

The National Academies of Sciences, Engineering, and Medicine's forums and roundtables do not issue, review, or approve individual documents. The responsibility for the published Proceedings of a Workshop rests with the workshop rapporteurs and the institution.